Seelos Therapeutics (SEEL)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On May 21, 2021, the Company held the Meeting. At the Meeting, a total of 53,871,239 shares, or 68.81% of the Company's Common Stock issued and outstanding as of the record date, were represented virtually or by proxy.
At the Meeting, the Company's stockholders considered five proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 12, 2021.
Set forth below is a brief description of each matter voted upon at the Meeting and the preliminary voting results with respect to each matter. The preliminary voting results set forth below are subject to change. If these results change, the Company will file an amendment to this Current Report on Form 8-K to disclose the final results within four business days after they are known.
Proposal No. 1: To elect two Class II directors, Raj Mehra, Ph.D. and Brian Lian, Ph.D., nominated by the Company's Board of Directors, to serve until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
NomineeForWithheldBroker Non-Votes
Raj Mehra, Ph.D.33,831,5772,886,55717,153,105
Brian Lian, Ph.D.33,759,9282,958,20617,153,105

Proposal No. 2: To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.
Proposal No. 3: To approve the reincorporation of the Company from the State of Nevada to the State of Delaware.
ForAgainstAbstentionsBroker Non-Votes
Proposal No. 4: To conduct an advisory (non-binding) vote on executive compensation.
ForAgainstAbstentionsBroker Non-Votes
Proposal No. 5: To approve an amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock, par value $0.001 per share, to a total of 240,000,000.
ForAgainstAbstentionsBroker Non-Votes